AR027591A1 - Inmunogeno para el tratamiento de la aterosclerosis; vacunas formuladas con dicho inmunogeno y procedimiento para el tratamiento o profilaxis de laaterosclerosis utilizando dicho inmunogeno. - Google Patents
Inmunogeno para el tratamiento de la aterosclerosis; vacunas formuladas con dicho inmunogeno y procedimiento para el tratamiento o profilaxis de laaterosclerosis utilizando dicho inmunogeno.Info
- Publication number
- AR027591A1 AR027591A1 ARP010100975A ARP010100975A AR027591A1 AR 027591 A1 AR027591 A1 AR 027591A1 AR P010100975 A ARP010100975 A AR P010100975A AR P010100975 A ARP010100975 A AR P010100975A AR 027591 A1 AR027591 A1 AR 027591A1
- Authority
- AR
- Argentina
- Prior art keywords
- apolipoprotein
- inhibition
- immunogen
- treatment
- apolipoproteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0012—Lipids; Lipoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan inmunogenos que comprenden apolipoproteínas, o fragmentos o derivados de éstas, las cuales en su forma nativa de apolipoproteínas tienen almenos una de las siguietnes actividades: (a) la inhibicion de la union de apolipoproteína A a s u receptor, y/o (b) la inhibicion de la lipoproteína lipasa. Unejemplo de una de dichas apolipoproteínas es la apolipoproteína C-III. También se proporciona (ApoCIII). También se proporcionan vacunas que comprenden dichosinmunogenos, que son potentes en la rpevencion o reduccion de la formacion de placa aterosclerotica durante periodos prolongados de tiempo, reduciendo así elpotencial de que la aterosclerosis conduzca a enfermedades coronarias o cerebrovasculares. Consiguientemente, se proporcio na un nuevo procedimiento detratamiento de aterosclerosis por inhibicion selectiva de la actividad de apolipoproteínas específicas en un huésped humano, y en un aspecto preferido de lainvencion, la apolipoproteína es ApoCIII, que comprende administra r un agente que da como resultado la inhibicion selectiva de la actividad apolipoproteína enun humano. También se proporcionan procedimientos de tratamiento o prevencion de la aterosclerosis por vacunacion activa, o por vacunacion pasiva mediante laa dministracion a un pasciente de una anticuerpo que es capaz de unirse a una apolipoproteína que tiene al menos una de las siguientes actividades: (a) lainhibicion de la union de apolipoproteína A a su receptor, y/o (b) la inhibicion de la lipoproteín a lipasa; y en este aspecto de la presente invencion, elanticuerpo se une preferiblemente e invalida la actividad de la ApoCIII. Se proporciona además el uso de inmunogneos o vacunas de la presente invencion enmedicina, y procedimientos para su produ ccion.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0005240A GB0005240D0 (en) | 2000-03-03 | 2000-03-03 | Vaccine |
| GB0022005A GB0022005D0 (en) | 2000-09-07 | 2000-09-07 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR027591A1 true AR027591A1 (es) | 2003-04-02 |
Family
ID=26243793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100975A AR027591A1 (es) | 2000-03-03 | 2001-03-01 | Inmunogeno para el tratamiento de la aterosclerosis; vacunas formuladas con dicho inmunogeno y procedimiento para el tratamiento o profilaxis de laaterosclerosis utilizando dicho inmunogeno. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20030165503A1 (es) |
| EP (1) | EP1267908B1 (es) |
| JP (1) | JP2003525883A (es) |
| KR (1) | KR20020079983A (es) |
| CN (1) | CN1418106A (es) |
| AR (1) | AR027591A1 (es) |
| AT (1) | ATE265860T1 (es) |
| AU (1) | AU2001246493A1 (es) |
| BR (1) | BR0108924A (es) |
| CA (1) | CA2401755A1 (es) |
| CZ (1) | CZ20022971A3 (es) |
| DE (1) | DE60103137T2 (es) |
| ES (1) | ES2219517T3 (es) |
| HU (1) | HUP0300099A3 (es) |
| IL (1) | IL151355A0 (es) |
| MX (1) | MXPA02008616A (es) |
| NO (1) | NO20024172L (es) |
| PL (1) | PL365424A1 (es) |
| WO (1) | WO2001064008A2 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0121171D0 (en) * | 2001-08-31 | 2001-10-24 | Glaxosmithkline Biolog Sa | Vaccine |
| BR0107175A (pt) * | 2000-09-04 | 2002-07-02 | Hyo Joon Kim | Peptìdeos miméticos para epitopo de apolipoproteìna b-100, concatemero e seus peptìdeos modificados, e composição de vacina compreendendo os mesmos |
| SE0103754L (sv) * | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
| US20030105003A1 (en) | 2001-04-05 | 2003-06-05 | Jan Nilsson | Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| EP1392732A2 (en) * | 2001-06-05 | 2004-03-03 | Genfit | Method for apo ciii measurement in apob and non apob containing particles |
| AU2002362612B2 (en) | 2001-09-28 | 2007-11-15 | Cedars-Sinai Medical Center | Prevention and treatment of restenosis by local administration of drug |
| US6930085B2 (en) * | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
| SE0302312D0 (sv) * | 2002-10-04 | 2003-08-27 | Forskarpatent I Syd Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
| WO2004030607A2 (en) * | 2002-10-04 | 2004-04-15 | Forskarpatent I Syd Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
| AT413945B (de) | 2003-01-14 | 2006-07-15 | Mattner Frank Dr | Impfstoff für die alzheimer-krankheit |
| GB0305794D0 (en) * | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Vaccine |
| GB0305790D0 (en) * | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Novel Composition |
| GB0305793D0 (en) * | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Vaccine |
| GB2404981A (en) * | 2003-08-15 | 2005-02-16 | Univ Geneve | Diagnostic method for stroke |
| KR100639397B1 (ko) * | 2004-03-18 | 2006-10-26 | (주)에스제이바이오메드 | 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물 |
| WO2005097206A2 (en) | 2004-04-06 | 2005-10-20 | Cedars-Sinai Medical Center | Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano |
| US20090280501A1 (en) * | 2005-04-11 | 2009-11-12 | Astrazeneca Ab | A Method And A Kit For Diagnosing Type 2 Diabetes, Metabolic Syndrome, Sub Clinical Atherosclerosis, Myocardial Infarct, Stroke Or Clinical Manifestations Of Diabetes |
| US8722630B2 (en) * | 2008-06-13 | 2014-05-13 | The General Hospital Corporation | Use of apolipoproteins to decrease inflammation |
| CU23736A1 (es) | 2009-05-04 | 2011-11-15 | Centro Inmunologia Molecular | Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso |
| US8506964B2 (en) | 2010-02-05 | 2013-08-13 | Cardiovax, Llc | Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis |
| RU2013126628A (ru) | 2010-11-12 | 2014-12-20 | Седарс-Синаи Медикал Сентер | Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм |
| WO2012074725A2 (en) | 2010-11-12 | 2012-06-07 | Cedars-Sinai Medical Center | Immunomodulatory methods and systems for treatment and/or prevention of hypertension |
| AU2014218583A1 (en) | 2013-02-25 | 2015-10-15 | Imetabolic Biopharma, Llc | Apolipoprotein c3 (apociii) antagonists and methods of their use to remove apociii inhibition of lipoprotein lipase (lpl) |
| CN103520713B (zh) * | 2013-10-16 | 2015-10-28 | 西北农林科技大学 | 一种ApoB100酵母重组疫苗及其制备方法和应用 |
| US11130798B2 (en) * | 2015-05-19 | 2021-09-28 | La Jolla Institute For Allergy And Immunology | Human APOB100 epitopes, methods and uses for modulating inflammatory responses, and treating adverse cardiovascular events, disease and atherosclerosis |
| CN106810606A (zh) * | 2015-11-27 | 2017-06-09 | 西藏自治区人民医院 | 一种载脂蛋白c-ⅲ抗原多肽及其多克隆抗体的制备与应用 |
| US20190201540A1 (en) * | 2016-05-24 | 2019-07-04 | Stc Unm | Immunogens, compositions, and methods for treating dyslipidemia |
| CN109689685A (zh) | 2016-07-08 | 2019-04-26 | 斯塔滕生物技术有限公司 | 抗apoc3抗体及其使用方法 |
| CN106519007B (zh) * | 2016-12-12 | 2019-07-02 | 王家祥 | 一种单链多肽及其在制备用于预防和治疗胃癌的药物中的应用 |
| WO2018193427A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| SG11202003980PA (en) | 2017-10-31 | 2020-05-28 | Staten Biotechnology B V | Anti-apoc3 antibodies and methods of use thereof |
| CN110590937A (zh) * | 2018-06-13 | 2019-12-20 | 杨宝田 | 一种人血载脂蛋白a1制品的制备方法及应用 |
| EP4237561A1 (en) | 2020-12-23 | 2023-09-06 | Argonaute Rna Limited | Treatment of cardiovascular disease |
| EP4402263A2 (en) | 2021-09-14 | 2024-07-24 | Argonaute Rna Limited | Treatment of cardiovascular disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6522486A (en) * | 1985-10-04 | 1987-04-24 | Biotechnology Research Partners Limited | Recombinant apolipoproteins and methods |
| WO1993000443A1 (en) * | 1991-06-26 | 1993-01-07 | Bio-Technology General Corp. | Purification of recombinant apolipoprotein e from bacteria |
| IL104015A0 (en) * | 1992-12-07 | 1993-05-13 | Doina International Ltd P | Method for immunization of mammals against atherosclerosis and pharmaceutical compositions for obtaining said immunization |
| EP0934337B1 (en) * | 1996-08-23 | 2007-12-19 | Esperion Therapeutics Inc. | A process for purifying apolipoprotein a or apolipoprotein e from human plasma |
| US6492185B1 (en) * | 1998-01-16 | 2002-12-10 | Abbott Laboratories | Immunoassay for detection of very low density lipoprotein and antibodies useful therefor |
| FR2776388B1 (fr) * | 1998-03-20 | 2006-04-28 | Lipha | Utilisation de recepteurs de la famille ror pour le criblage de substances utiles pour le traitement de l'atherosclerose |
| FR2780512B1 (fr) * | 1998-06-25 | 2003-10-17 | Lipha | Utilisation de recepteurs de la famille rev-erb pour le criblage de substances utiles dans le traitement des dysfonctionnements du metabolisme lipidique |
-
2001
- 2001-03-01 DE DE60103137T patent/DE60103137T2/de not_active Expired - Fee Related
- 2001-03-01 IL IL15135501A patent/IL151355A0/xx unknown
- 2001-03-01 CN CN01805933A patent/CN1418106A/zh active Pending
- 2001-03-01 AU AU2001246493A patent/AU2001246493A1/en not_active Abandoned
- 2001-03-01 BR BR0108924-2A patent/BR0108924A/pt not_active Application Discontinuation
- 2001-03-01 US US10/220,786 patent/US20030165503A1/en not_active Abandoned
- 2001-03-01 KR KR1020027011547A patent/KR20020079983A/ko not_active Application Discontinuation
- 2001-03-01 CZ CZ20022971A patent/CZ20022971A3/cs unknown
- 2001-03-01 WO PCT/EP2001/002326 patent/WO2001064008A2/en active IP Right Grant
- 2001-03-01 HU HU0300099A patent/HUP0300099A3/hu unknown
- 2001-03-01 AT AT01919363T patent/ATE265860T1/de not_active IP Right Cessation
- 2001-03-01 ES ES01919363T patent/ES2219517T3/es not_active Expired - Lifetime
- 2001-03-01 MX MXPA02008616A patent/MXPA02008616A/es unknown
- 2001-03-01 JP JP2001562922A patent/JP2003525883A/ja active Pending
- 2001-03-01 PL PL01365424A patent/PL365424A1/xx not_active Application Discontinuation
- 2001-03-01 EP EP01919363A patent/EP1267908B1/en not_active Expired - Lifetime
- 2001-03-01 CA CA002401755A patent/CA2401755A1/en not_active Abandoned
- 2001-03-01 AR ARP010100975A patent/AR027591A1/es unknown
-
2002
- 2002-09-02 NO NO20024172A patent/NO20024172L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0300099A3 (en) | 2004-10-28 |
| WO2001064008A2 (en) | 2001-09-07 |
| ES2219517T3 (es) | 2004-12-01 |
| CZ20022971A3 (cs) | 2003-02-12 |
| DE60103137D1 (de) | 2004-06-09 |
| KR20020079983A (ko) | 2002-10-21 |
| AU2001246493A1 (en) | 2001-09-12 |
| CN1418106A (zh) | 2003-05-14 |
| CA2401755A1 (en) | 2001-09-07 |
| MXPA02008616A (es) | 2003-02-24 |
| PL365424A1 (en) | 2005-01-10 |
| HUP0300099A2 (en) | 2003-05-28 |
| EP1267908B1 (en) | 2004-05-06 |
| IL151355A0 (en) | 2003-04-10 |
| WO2001064008A3 (en) | 2002-02-14 |
| JP2003525883A (ja) | 2003-09-02 |
| NO20024172L (no) | 2002-11-01 |
| BR0108924A (pt) | 2003-04-29 |
| DE60103137T2 (de) | 2005-05-25 |
| EP1267908A1 (en) | 2003-01-02 |
| NO20024172D0 (no) | 2002-09-02 |
| US20030165503A1 (en) | 2003-09-04 |
| ATE265860T1 (de) | 2004-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR027591A1 (es) | Inmunogeno para el tratamiento de la aterosclerosis; vacunas formuladas con dicho inmunogeno y procedimiento para el tratamiento o profilaxis de laaterosclerosis utilizando dicho inmunogeno. | |
| Im et al. | Effect of teriparatide on healing of atypical femoral fractures: a systemic review | |
| BRPI0610093A2 (pt) | composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente | |
| SE0103754L (sv) | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid | |
| HK1087018A1 (en) | Peptide-based passive immunization therapy for treatment of atherosclerosis | |
| AR024074A1 (es) | FRAGMENTO ABETA UNIDO A UN PÉPTIDO PORTADOR PARA PREVENIR O TRATAR ENFERMEDADES ASOCIADAS CON DEPoSITOS AMILOIDES DE ABETA, COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN, Y SU USO EN LA PREPARACION DE MEDICAMENTOS. | |
| BRPI0412202A (pt) | emplastro para imunização tendo um arranjo de microprojeções, e método | |
| CY1107074T1 (el) | Συνθεση εναντιομερων 4-αμινο-θαλιδομιδης | |
| DE68921389D1 (de) | Influenzaimpfstoff und Adjuvanten. | |
| BRPI0517963A2 (pt) | piridinureas antralinamidas como inibidores de receptores de cinases do fator de crescimento endotelial vascular | |
| UY26456A1 (es) | Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen. | |
| BR0310088A (pt) | Pré-direcionamento de droga por meio de anticorpos biespecìficos e constructos haptênicos compreendendo um veìculo peptìdico e o(s) agente(s) ativo(s) | |
| AR056806A1 (es) | Moleculas quimericas de anticuerpo rankl- pth/ pthrp | |
| AR036315A1 (es) | Vacuna para la aterosclerosis con fragmentos de apociii, anticuerpos anti apociii | |
| CY1110048T1 (el) | Μεθοδος για την παραγωγη αλατων του τιοτροπιου | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| DE60030777D1 (de) | Durch ein sol-gel verfahren hergestellte bioaktive silicafasern und zugehörige verfahren und anwendungen | |
| HUP0401605A2 (hu) | Szembetegségek kezelésére szolgáló integrin gátlók | |
| ECSP044961A (es) | Acido n-(5-clorosaliciloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides | |
| WO2006071896A3 (en) | Epitope-based sars vaccine | |
| BRPI0409387B8 (pt) | complexo de alvejamento de tecido mole de tório-227 e um agente complexante, uso do mesmo, composição farmacêutica, método para a formação de um complexo, e, kit para uso em um método para o tratamento de doença de tecido mole em um indivíduo mamífero | |
| WO2004080375A3 (en) | Vaccine therapy of atherosclerosis | |
| WO2004030607A3 (en) | Peptide-based passive immunization therapy for treatment of atherosclerosis | |
| WO2004081045A3 (en) | Vaccine related to modified apolipoprotein c-iii | |
| ATE463252T1 (de) | Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |